Raymond James lowered the firm’s price target on ICU Medical (ICUI) to $180 from $187 and keeps a Strong Buy rating on the shares. The Q2 beat gives the firm confidence that underlying business momentum is improving, and this trend should to continue with various new product launches and ongoing efforts to optimize the cost structure, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI: